Advertisement
Screener

Disc Medicine, Inc. (IRON) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

Disc Medicine, Inc. Selling, General and Administrative Expense

Disc Medicine, Inc. (IRON) reported Selling, General and Administrative Expense of $18.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30

  • Disc Medicine, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $18.14M, a 20.22% increase year-over-year.
  • Disc Medicine, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $23.62M, a 93.88% increase year-over-year.
  • Disc Medicine, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $20.75M, a 112.71% increase year-over-year.
  • Disc Medicine, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $17.36M, a 112.48% increase year-over-year.
  • Disc Medicine, Inc. selling, general and administrative expense for fiscal 2025 was $65.38M, a 97.83% increase from fiscal 2024.
  • Disc Medicine, Inc. selling, general and administrative expense for fiscal 2024 was $33.05M, a 51.18% increase from fiscal 2023.
  • Disc Medicine, Inc. selling, general and administrative expense for fiscal 2023 was $21.86M.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 12 month
2026-06-30$18.14M
10-Q · filed 2026-07-30
$41.76M
10-Q · filed 2026-07-30
$62.51M
derived: sum of 3 quarters · filed 2026-07-30
$79.87M
derived: sum of 4 quarters · filed 2026-07-30
2026-03-31$23.62M
10-Q · filed 2026-05-05
$44.37M
derived: sum of 2 quarters · filed 2026-05-05
$61.73M
derived: sum of 3 quarters · filed 2026-05-05
$76.82M
derived: sum of 4 quarters · filed 2026-07-30
2025-12-31$20.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$38.11M
derived: sum of 2 quarters · filed 2026-02-26
$53.20M
derived: sum of 3 quarters · filed 2026-07-30
$65.38M
10-K · filed 2026-02-26
2025-09-30$17.36M
10-Q · filed 2025-11-06
$32.45M
derived: sum of 2 quarters · filed 2026-07-30
$44.64M
10-Q · filed 2025-11-06
$54.39M
derived: sum of 4 quarters · filed 2026-07-30
2025-06-30$15.09M
10-Q · filed 2026-07-30
$27.27M
10-Q · filed 2026-07-30
$37.03M
derived: sum of 3 quarters · filed 2026-07-30
$45.20M
derived: sum of 4 quarters · filed 2026-07-30
2025-03-31$12.18M
10-Q · filed 2026-05-05
$21.94M
derived: sum of 2 quarters · filed 2026-05-05
$30.11M
derived: sum of 3 quarters · filed 2026-05-05
$37.47M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$9.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$17.92M
derived: sum of 2 quarters · filed 2026-02-26
$25.29M
derived: sum of 3 quarters · filed 2026-02-26
$33.05M
10-K · filed 2026-02-26
2024-09-30$8.17M
10-Q · filed 2025-11-06
$15.54M
derived: sum of 2 quarters · filed 2025-11-06
$23.30M
10-Q · filed 2025-11-06
2024-06-30$7.37M
10-Q · filed 2025-08-07
$15.13M
10-Q · filed 2025-08-07
2024-03-31$7.76M
10-Q · filed 2025-05-07
2023-12-31$21.86M
10-K · filed 2026-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82